US · XFOR · BIOTECHNOLOGY
X4 Pharmaceuticals, Inc. (XFOR) intrinsic value and stock valuation
$3.00as of 2026-11-21 · Mkt cap 391.43M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
X4 Pharmaceuticals, Inc. DCF and intrinsic value
InvestorsCraft values XFOR with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from XFOR’s statements →
X4 Pharmaceuticals, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2015–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $35.1M | $2.56M | $0.00 | $0.00 | $0.00 |
| Operating income | -$-86.88M | -$-36.4M | -$-107.52M | -$-87.57M | -$-75.35M |
| Net income | -$-79.2M | -$-37.45M | -$-101.17M | -$-93.87M | -$-88.7M |
| EPSd | -$-1.87M | -$-5.59M | -$-17.06M | -$-44.28M | -$-103.14M |
| Operating cash flow | -$-85.62M | -$-130.9M | -$-96.51M | -$-77.1M | -$-70.91M |
| Capital expenditure | -$-3M | -$-7.33M | -$-60K | -$-100K | -$-610K |
| Free cash flow | -$-88.62M | -$-138.23M | -$-96.57M | -$-77.2M | -$-71.52M |
| Total assets | $290.5M | $146.5M | $147.3M | $155.6M | $117.2M |
| Total debt | $77.3M | $78.1M | $58.3M | $38.4M | $39.8M |
| Net debt | -$-139.76M | $22.4M | -$-40.94M | -$-83.3M | -$-42M |
| Total equity | $186.3M | $22.2M | $51.1M | $74.1M | $64.4M |
| Cash and short-term investments | $253M | $102.1M | $114.2M | $121.7M | $81.8M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $35.1M | $2.56M | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $6.26M | $800K | $0.00 | $0.00 | $1.89M |
| Gross profit | $28.9M | $1.76M | $0.00 | $0.00 | -$-1.89M |
| Research and development expenses | $72.2M | $81.6M | $72M | $61.1M | $48.8M |
| Selling, general and administrative expenses | $43.5M | $61.5M | $35.5M | $27M | $24.7M |
| Other expenses | $0.00 | -$-105M | $0.00 | -$-510K | $0.00 |
| Operating expenses | $115.7M | $38.2M | $107.5M | $87.6M | $73.5M |
| Cost and expenses | $122M | $39M | $107.5M | $87.6M | $75.4M |
| Interest income | $4.58M | $5.77M | $4.58M | $220K | $10K |
| Interest expense | $8.88M | $8.77M | $5.78M | $3.99M | $3.64M |
| Depreciation and amortization | $1.28M | $800K | $420K | $510K | $1.89M |
| Ebitda | -$-69M | -$-27.58M | -$-94.89M | -$-89.33M | -$-83.14M |
| Operating income | -$-86.88M | -$-36.4M | -$-107.52M | -$-87.57M | -$-75.35M |
| Total other income/expenses, net | $7.72M | -$-740K | $6.43M | -$-6.27M | -$-13.33M |
| Income before tax | -$-79.16M | -$-37.14M | -$-101.09M | -$-93.84M | -$-88.68M |
| Income tax expense | $40K | $310K | $80K | $30K | $20K |
| Net income | -$-79.2M | -$-37.45M | -$-101.17M | -$-93.87M | -$-88.7M |
| Weighted average shares outstanding | $42.3M | $6.7M | $5.93M | $2.12M | $860K |
| Weighted average diluted shares outstanding | $42.3M | $6.7M | $5.93M | $2.12M | $860K |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $253M | $102.1M | $114.2M | $121.7M | $81.8M |
| Net receivables | $570K | $1.71M | $560K | $1.15M | $750K |
| Inventory | $4.48M | $2.82M | $0.00 | $0.00 | $0.00 |
| Total current assets | $261.6M | $112.2M | $122.1M | $128.7M | $87.9M |
| Property, plant and equipment, net | $1.59M | $4.84M | $6.39M | $8.33M | $10.2M |
| Goodwill and intangible assets | $26.6M | $27.4M | $17.4M | $17.4M | $17.4M |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $1.32M |
| Total non-current assets | $28.9M | $34.3M | $25.2M | $26.9M | $29.3M |
| Total assets | $290.5M | $146.5M | $147.3M | $155.6M | $117.2M |
| Accounts payable | $5.7M | $8.62M | $8.95M | $7.78M | $4.28M |
| Short-term debt | $990K | $1.25M | $1.1M | $2.51M | $1.87M |
| Deferred revenue | $460K | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $25.8M | $32.9M | $22.9M | $22.3M | $14M |
| Long-term debt | $76.3M | $76.8M | $57.2M | $35.9M | $37.9M |
| Deferred revenue, non-current | $620K | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $78.4M | $91.4M | $73.3M | $59.2M | $38.7M |
| Capital lease obligations | $990K | $2.66M | $3.71M | $4.8M | $4.78M |
| Total liabilities | $104.2M | $124.3M | $96.2M | $81.5M | $52.8M |
| Common stock | $90K | $10K | $170K | $120K | $30K |
| Retained earnings | -$-594.55M | -$-515.36M | -$-477.9M | -$-376.74M | -$-282.87M |
| Accumulated other comprehensive income (loss) | -$-110K | -$-120K | -$-120K | -$-120K | -$-120K |
| Total equity | $186.3M | $22.2M | $51.1M | $74.1M | $64.4M |
| Total investments | $36M | $46.4M | $15M | $0.00 | $1.32M |
| Total debt | $77.3M | $78.1M | $58.3M | $38.4M | $39.8M |
| Net debt | -$-139.76M | $22.4M | -$-40.94M | -$-83.3M | -$-42M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-79.2M | -$-37.45M | -$-101.17M | -$-93.87M | -$-88.7M |
| Depreciation and amortization | $1.28M | $800K | $420K | $510K | $1.89M |
| Stock-based compensation | $4.3M | $8.2M | $8.69M | $5.2M | $0.00 |
| Change in working capital | -$-2.58M | $2.67M | $340K | $5.74M | -$-1.5M |
| Accounts receivable | $500K | -$-1.07M | $0.00 | $0.00 | $0.00 |
| Inventory | -$-1.66M | -$-2.82M | $0.00 | $0.00 | $0.00 |
| Accounts payable | -$-2.98M | -$-290K | $1.23M | $3.42M | $1.17M |
| Net cash provided by operating activities | -$-85.62M | -$-130.9M | -$-96.51M | -$-77.1M | -$-70.91M |
| Investments in property, plant and equipment | -$-3M | -$-330K | -$-60K | -$-100K | -$-610K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | $8.15M | $67M | -$-14.88M | -$-100K | -$-610K |
| Common stock issued | $238.5M | $290K | $60M | $122.6M | $76.3M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | -$-2M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $238.6M | $20.3M | $88.5M | $117.2M | $74.3M |
| Net change in cash | $161.4M | -$-43.77M | -$-22.78M | $39.9M | $2.81M |
| Cash at end of period | $217.9M | $56.5M | $100.3M | $123M | $81.8M |
| Operating cash flow | -$-85.62M | -$-130.9M | -$-96.51M | -$-77.1M | -$-70.91M |
| Capital expenditure | -$-3M | -$-7.33M | -$-60K | -$-100K | -$-610K |
| Free cash flow | -$-88.62M | -$-138.23M | -$-96.57M | -$-77.2M | -$-71.52M |
Line items
Line items
Line items
About X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd. grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical applications, including therapeutic, preventive, and diagnostic uses. The company maintains its corporate headquarters in Boston, Massachusetts.
- CEO
- Adam R. Craig
- Employees
- 45
- Beta
- 0.35
Explore
Frequently asked questions
What is the intrinsic value of X4 Pharmaceuticals, Inc. (XFOR)?
InvestorsCraft does not currently publish an intrinsic value for XFOR. How the IC value is calculated.
Is XFOR undervalued?
InvestorsCraft does not publish an undervaluation signal for XFOR at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.